[O]ral semaglutide 14 mg (or flexible dosing, in PIONEER 7) was generally more effective at improving multiple cardiometabolic risk factors — including HbA 1c, [body weight], SBP, and LDL ...

Novo Nordisk's late stage diabetes candidate semaglutide ... more convenient weekly dosing schedule. Novo is also developing semaglutide in a patient-friendly pill form. Launched in 2015 ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM ... containing semaglutide generated $25 billion ...